Literature DB >> 8459048

The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. BCSH Haemostasis and Thrombosis Task Force.

B T Colvin1, T W Barrowcliffe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8459048      PMCID： PMC501136          DOI： 10.1136/jcp.46.2.97

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  28 in total

1.  Protamine--the need to determine the dose. Comparison of a simple protamine titration method with an empirical dose regimen for reversal of heparinisation following cardiopulmonary bypass.

Authors:  J F Keeler; M V Shah; S D Hansbro
Journal:  Anaesthesia       Date:  1991-11       Impact factor: 6.955

Review 2.  Low molecular weight heparin.

Authors:  J Hirsh; M N Levine
Journal:  Blood       Date:  1992-01-01       Impact factor: 22.113

3.  Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum.

Authors:  T Dahlman; N Lindvall; M Hellgren
Journal:  Br J Obstet Gynaecol       Date:  1990-03

Review 4.  Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.

Authors:  R Collins; A Scrimgeour; S Yusuf; R Peto
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

Review 5.  Pharmacokinetics of heparin and low molecular weight heparin.

Authors:  B Boneu; C Caranobe; P Sie
Journal:  Baillieres Clin Haematol       Date:  1990-07

6.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.

Authors:  J Hsia; W P Hamilton; N Kleiman; R Roberts; B R Chaitman; A M Ross
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

7.  Neutralization of enoxaparine-induced bleeding by protamine sulfate.

Authors:  J Van Ryn-McKenna; L Cai; F A Ofosu; J Hirsh; M R Buchanan
Journal:  Thromb Haemost       Date:  1990-04-12       Impact factor: 5.249

8.  Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.

Authors:  R D Hull; G E Raskob; D Rosenbloom; A A Panju; P Brill-Edwards; J S Ginsberg; J Hirsh; G J Martin; D Green
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

9.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; G F Pineo; D Green; A A Trowbridge; C G Elliott; R G Lerner; J Hall; T Sparling; H R Brettell
Journal:  N Engl J Med       Date:  1992-04-09       Impact factor: 91.245

10.  Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.

Authors:  P F Leyvraz; F Bachmann; J Hoek; H R Büller; M Postel; M Samama; M D Vandenbroek
Journal:  BMJ       Date:  1991-09-07
View more
  6 in total

1.  Uses of heparin.

Authors:  C N Chesterman; B H Chong
Journal:  BMJ       Date:  1993-04-03

2.  Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis.

Authors:  E Attanasio; P Russo; G Carunchio; L Caprino
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

3.  Outpatient Therapy of Deep Vein Thrombosis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-01       Impact factor: 2.300

Review 4.  Anticoagulation therapy in children.

Authors:  Milind D Ronghe; Christina Halsey; Nicholas J Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  Prevention and treatment of venous thromboembolism.

Authors:  G F Pineo; R D Hull
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

Review 6.  Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation.

Authors:  A R Webb; M G Mythen; D Jacobson; I J Mackie
Journal:  Intensive Care Med       Date:  1995-01       Impact factor: 17.440
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.